Pharmacy giant Write has announced it's officially closed all of its stores. The company made the announcement on its website on Friday. Write aid filed for Chapter 11 bankruptcy back in May.Now, the company has promised a smooth transfer for customers with prescriptions there. So, if you're one of them, you can go to the Write Aid website to request your records and find a new. ...

Core Points - Rite Aid has officially closed all its stores following its Chapter 11 bankruptcy filing, marking its second bankruptcy since October 2023 [1][7] - The company faced significant financial challenges exacerbated by changes in the retail and healthcare sectors, with a reported loss of $750 million in the previous fiscal year [2][7] - Rite Aid's website now only provides a service for former customers to find new pharmacies and request pharmacy records [3] Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy in May 2023 and announced the closure of all its stores as part of its bankruptcy plan [1][4] - At its peak, Rite Aid operated thousands of stores, but by May 2023, it had reduced to 1,240 locations across 15 states [6] Transition of Services - The company entered into agreements to transition its pharmacy services and assets to other pharmacy chains, including CVS Pharmacy and Walgreens, ensuring a smooth transfer of customer prescriptions [4] - CEO Matt Schroeder emphasized the importance of maintaining uninterrupted pharmacy services for customers and preserving jobs for associates during the transition [2][4] Asset Sales - Rite Aid auctioned its in-house ice cream brand, Thirty Ice Cream, to Hilrod Holdings for $19.2 million, with the transaction approved by a federal judge [5] - The company had previously owned Thrifty PayLess, Inc., which was part of the assets sold during the bankruptcy process [5] Debt Situation - After emerging from bankruptcy in 2024, Rite Aid was reported to still have $2.5 billion in debt [8]

Core Insights - PharmaCorp RX Inc. has completed the acquisition of three community pharmacy businesses, enhancing its presence in both Western and Eastern Canada [1][4] Western Canada Acquisitions - The company acquired two PharmaChoice Canada bannered pharmacies in Western Canada for an aggregate purchase price of $3,400,000, with 75% paid in cash and 25% through the issuance of common shares [2] - The common shares were priced based on the volume weighted average trading price on the TSX Venture Exchange over a specified period prior to the closing date [2] Eastern Canada Acquisition - PharmaCorp also acquired a PharmaChoice Canada bannered pharmacy in Eastern Canada for $5,300,000, funded through cash on hand and available credit [3] - No finder's fees were incurred in connection with these acquisitions [3] Strategic Growth - The acquisitions are part of PharmaCorp's disciplined growth strategy and strengthen its strategic alliance with PharmaChoice Canada [4] - The company aims to expand its national footprint while preserving independent legacies and ensuring continuity of care for patients [4] - PharmaCorp plans to remain active in pursuing further acquisitions in the near future [4] Company Overview - PharmaCorp currently operates seven PharmaChoice Canada bannered pharmacies and intends to continue acquiring both PharmaChoice and independently owned pharmacies [5] - The company is open to discussions with pharmacy owners considering succession or sale, emphasizing a commitment to seamless transitions [6]

Core Viewpoint - PharmaCorp RX Inc. has filed a preliminary short form base shelf prospectus to qualify the distribution of up to $100 million in various securities over a 25-month period, enhancing its ability to access capital markets for growth and acquisitions [2][3]. Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [5]. - The company operates four pharmacies under the PharmaChoice Canada banner and aims to acquire more pharmacies, rebranding them under its platform [5]. Financial Strategy - The base shelf prospectus will allow PharmaCorp to issue common shares, preferred shares, warrants, debt securities, subscription receipts, units, or any combination thereof, based on financial requirements and market conditions [2]. - The specific terms of any offerings will be detailed in prospectus supplements filed with Canadian securities regulatory authorities [2]. Corporate Development - The filing of the base shelf prospectus is seen as a milestone in PharmaCorp's corporate development, providing flexibility to access capital markets as acquisition opportunities arise [3]. - The strategic alliance with PharmaChoice Canada is highlighted as a key factor in advancing the company's national growth and operations platform [3].

Core Points - Bankruptcy is a legal process that provides relief from overwhelming debts but comes with specific limitations and obligations that must be adhered to [6][10][11] Group 1: Bankruptcy Process and Obligations - After filing for bankruptcy, individuals must complete a debtor education course to receive a discharge, and failure to comply with court orders can lead to case dismissal [1][2] - Both Chapter 7 and Chapter 13 bankruptcies require court oversight, including attending meetings and submitting documents [2][3] - There are waiting periods before individuals can file for bankruptcy again, with Chapter 7 requiring an 8-year wait and Chapter 13 a 4-year wait after a previous discharge [3][4] Group 2: Limitations Post-Bankruptcy - A bankruptcy filing significantly impacts credit reports, with Chapter 7 remaining for up to 10 years and Chapter 13 for up to 7 years, making it difficult to obtain new credit [6][7] - Certain debts, such as student loans, child support, and recent tax debts, are not dischargeable through bankruptcy [10] - Individuals cannot cosign loans immediately after bankruptcy due to being viewed as higher-risk borrowers [12][13] Group 3: Rebuilding and Financial Management - Rebuilding credit is essential after bankruptcy, and individuals are encouraged to adopt careful financial habits, including budgeting and using secured credit cards [14][15] - Honesty in future credit applications is crucial, as lying about past bankruptcy can lead to fraud charges [16][17] Group 4: Broader Implications - Bankruptcy can affect employment opportunities, particularly in finance-related jobs, and may complicate renting and insurance processes [20]

Core Points - The Swarthmore Avenue CVS Pharmacy has reopened, marking it as the first community pharmacy in the neighborhood, which enhances access to health and wellness essentials [1] Company Summary - CVS Health® has celebrated the reopening of the Pacific Palisades CVS Pharmacy store, indicating a commitment to improving community health access [1]

Core Viewpoint - PharmaCorp RX Inc. has entered into definitive share purchase agreements to acquire a 100% interest in two PharmaChoice Canada pharmacies in Western Canada for an aggregate purchase price of $3,400,000 [1][2]. Acquisition Details - The purchase price will be satisfied with 75% cash and 25% through the issuance of common shares, with the share price based on the volume weighted average trading price over a specified period [2]. - The acquisitions are expected to close around October 1, 2025, pending customary closing conditions [3]. Strategic Implications - The transactions demonstrate PharmaCorp's capability to execute accretive acquisitions, aligning with its strategic alliance with PharmaChoice Canada [4]. - PharmaCorp currently operates four PharmaChoice Canada pharmacies and plans to continue acquiring more pharmacies under this brand [4].

Financial Performance - Normalised revenue increased by 82.3% to $6.0085 billion[12, 21], and normalised EBIT increased by 41.4% to $834.5 million[11, 12, 21, 74] - Statutory NPAT increased by 40% to $579.1 million[12] - Pro-forma revenue reached $9.6 billion[13, 27], and pro-forma EBIT was $903.4 million[13, 27] - Net debt to normalised EBITDA ratio is 0.85x[14, 18, 37] Growth and Expansion - Chemist Warehouse (CW) retail network sales increased by 14% to $10.3 billion[10] - Australian CW franchise stores experienced 11.3% like-for-like sales growth[10, 30] - The company has expanded to 674 Chemist Warehouse stores globally[10, 46, 74] Synergies and Efficiencies - Synergies target upgraded to $100 million per annum by year four[10, 56, 58] - Distribution Centre (DC) volumes increased by 29% to over 532 million units[10, 57] - Logistics costs decreased by 11% per unit[10] Product Strategy - Over 20% growth in FY25 sales of own and exclusive label products[10, 54] - Launched Wagner generic medicines in November 2024[10, 54]

Core Viewpoint - PharmaCorp Rx Inc. reported strong operational momentum and financial results for Q2 2025, highlighting its national acquisition strategy and growth in pharmacy-level contributions [2][4]. Financial Highlights - The company generated revenues from three operating pharmacies, with same-store sales increasing by 11.3% year-over-year compared to Q2 2024 [8]. - Prescription volumes rose by 3.5% year-over-year, indicating sustained patient engagement [8]. - The net loss for the quarter was attributed to investments in corporate infrastructure and deferred executive compensation from 2024 [5][8]. Operational Update - Key investments were made in systems, personnel, and integration processes to support scalable national growth [5]. - The company completed the acquisition of its fourth pharmacy in Western Canada, enhancing its national footprint [6][8]. Subsequent Events - On August 13, 2025, PharmaCorp entered into a credit agreement with CIBC, providing up to $20.5 million in committed credit facilities to support its acquisition strategy [7]. - A separate $5 million credit facility was established to support the Pharmacist Co-Ownership Program, enabling pharmacists to acquire ownership positions [7]. Pipeline Progress - PharmaCorp is actively working to finalize purchase and sale agreements related to previously announced letters of intent, expecting to close additional transactions in the second half of the year [9]. Company Overview - PharmaCorp Rx Inc. focuses on empowering pharmacists to become equity partners while supporting the continuity of care and succession for retiring pharmacy owners [12]. - The company operates four PharmaChoice Canada bannered pharmacies and aims to acquire more pharmacies under this brand [12].

Core Insights - PharmaCorp RX Inc. has secured a credit agreement with Canadian Imperial Bank of Commerce (CIBC) for up to $20,500,000 in committed credit facilities, which includes a $10,000,000 accordion feature and a $1,000,000 Visa credit facility to support its acquisition strategy and operational expansion [1][4][8] Credit Facilities - The credit facilities consist of a $17,500,000 committed acquisition term facility with a $10,000,000 accordion feature, allowing for increased borrowing capacity as acquisition opportunities arise, and a $3,000,000 committed revolving operating line for working capital [8] - A separate $5,000,000 credit facility is established to support the Pharmacist Co-Ownership Program, aimed at addressing the capital access challenges faced by pharmacists [2][3] Pharmacist Co-Ownership Program - The Pharmacist Co-Ownership Program provides loans to pharmacists wishing to acquire ownership in the PharmaCorp pharmacy where they work, financing up to 100% of their equity investment with competitive rates and repayment terms of up to 15 years [3][4] - This program is designed to remove barriers to ownership and facilitate long-term wealth creation for pharmacists through co-ownership with PharmaCorp [4] Company Operations - PharmaCorp currently operates four PharmaChoice Canada bannered pharmacies and plans to continue acquiring additional PharmaChoice Canada branded pharmacies as they become available [5] - The company is also open to acquiring independently owned non-PharmaChoice Canada bannered pharmacies and will operate them under the PharmaChoice Canada banner post-acquisition [5][6]